Basal Cell Carcinoma Clinical Trial
Official title:
A Prospective, Open, Single-arm, Single Center, Phase II Trial to Assess the Efficacy of Anti-PD1 Antibody in Combination With Pulsed Hedgehog Inhibitor in Advanced Basal Cell Carcinoma.
The purpose of this study is to evaluate the tumour response, safety and induction of immune response in patients with advanced BCC treated with a combination of anti-PD1 antibody and pulsed hedgehog inhibitor.
A prospective, open, single-arm, single center, phase II trial to assess the efficacy of anti-PD1 antibody in combination with pulsed Hedgehog inhibitor in advanced Basal Cell Carcinoma. 20 patients with advanced BCC will be included in the trial. No blinding or randomization will be conducted in this open label, non-randomized clinical trial. All of the patients will receive the investigative treatment (combination of anti-PD1 antibody and pulsed HHI therapy). The tumor response will be evaluated comparing tumour size at baseline, at each assessment, and 26 weeks after treatment initiation. The study duration from screening visit to the End of Study visit is 32 weeks with a Follow-Up 1 Visit at week 28 and Follow-Up 2 Visit at week 32. The duration of the translational part (secondary objectives) of the study is up to 24 months. If the best response any time at week 26 is partial response, patients will be offered to continue at least one of the study drugs until complete response or until a maximum of 2 years. The evaluation during this period will correspond to the standard of care with laboratory tests at each follow up and imaging every 12 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04552990 -
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT04229277 -
Fast Track Diagnosis of Skin Cancer by Advanced Imaging
|
N/A | |
| Completed |
NCT05608902 -
Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
|
||
| Completed |
NCT05077033 -
Intratumoral phIL12 GET
|
Phase 1 | |
| Active, not recruiting |
NCT04928222 -
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04929535 -
Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment
|
Phase 2 | |
| Completed |
NCT02662244 -
Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
|
N/A | |
| Completed |
NCT00959647 -
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
|
Phase 2 | |
| Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
| Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
| Completed |
NCT00473343 -
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT06024629 -
cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
|
||
| Not yet recruiting |
NCT05324202 -
New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management
|
N/A | |
| Withdrawn |
NCT04099446 -
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
|
||
| Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
| Completed |
NCT01201915 -
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01260987 -
Fractional CO2 Laser Assisted Photodynamic Therapy
|
Phase 2/Phase 3 | |
| Completed |
NCT01208831 -
An East Asian Study of LDE225
|
Phase 1 | |
| Completed |
NCT01014819 -
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
|
N/A | |
| Completed |
NCT00472043 -
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma
|
Phase 3 |